

LRIG1 Protein, Human, Recombinant (His)

General Information

Synonyms:	LIG1;Img;LRIG1;LIG-1;D6Bwg0781e
Protein Construction:	Ala35-Ser779
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q96JA1-1
Molecular Weight:	83 kDa (predicted). Due to glycosylation, the protein migrates to 85-105 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human LRIG1, His Tag at 2µg/ml (100µl/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 5.3ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing 50 mM MES, 150 mM NaCl, 1 mM EDTA (pH 5.0). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0). The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in

combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.

Reference

An Y, et al. Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer. *Medicine (Baltimore)*. 2015 Nov;94(47):e208doi: 10.1097/MD.000000000000208PMID: 26632716; PMCID: PMC5058985.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481